Autologous CD7-targeting CAR T cells — Competitive Intelligence Brief

Autologous CD7-targeting CAR T cells (Autologous CD7-targeting CAR T cells) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CAR T cell therapy. Area: Oncology.

phase 2 CAR T cell therapy CD7 Oncology Biologic

Target snapshot

Autologous CD7-targeting CAR T cells (Autologous CD7-targeting CAR T cells) — Hebei Senlang Biotechnology Inc., Ltd.. Autologous CD7-targeting CAR T cells are engineered patient-derived T cells that recognize and kill CD7-expressing cells, primarily used to target T-cell malignancies.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Autologous CD7-targeting CAR T cells TARGET	Autologous CD7-targeting CAR T cells	Hebei Senlang Biotechnology Inc., Ltd.	phase 2	CAR T cell therapy	CD7
CAR T cells	CAR T cells	Memorial Sloan Kettering Cancer Center	phase 3	CAR T cell therapy	Tumor-associated antigens (e.g., CD19, BCMA, mesothelin depending on construct)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CAR T cell therapy class)

1. AffyImmune Therapeutics, Inc. · 1 drug in this class
2. Allife Medical Science and Technology Co., Ltd. · 1 drug in this class
3. Chongqing Precision Biotech Co., Ltd · 1 drug in this class
4. Hebei Senlang Biotechnology Inc., Ltd. · 1 drug in this class
5. Memorial Sloan Kettering Cancer Center · 1 drug in this class